TY - JOUR
T1 - Genomic deletions upstream of lamin B1 lead to atypical autosomal dominant leukodystrophy
AU - Nmezi, Bruce
AU - Giorgio, Elisa
AU - Raininko, Raili
AU - Lehman, Anna
AU - Spielmann, Malte
AU - Koenig, Mary Kay
AU - Adejumo, Rahmat
AU - Knight, Melissa
AU - Gavrilova, Ralitza
AU - Alturkustani, Murad
AU - Sharma, Manas
AU - Hammond, Robert
AU - Gahl, William A.
AU - Toro, Camilo
AU - Brusco, Alfredo
AU - Padiath, Quasar S.
N1 - Funding Information:
The Article Processing Charge was funded by NIH.
Funding Information:
This work was supported by funds from the University of Pittsburgh to B.N., Q.S.P., the Fondazione Umberto Veronesi (postdoctoral fellowship 2017 to E.G.), the “Associazione E. E. Rulfo per la ricerca biomedica” to AB, and the National Institutes of Health (NIH) Common Fund through the NIH Undiagnosed Diseases Program/Undiagnosed Diseases Network.
Funding Information:
B. Nmezi reports no disclosures. E. Giorgio holds patents for 3 siRNA sequences targeting a single allele of the human Lam-inB1 gene as therapeutic option for Autosomal Dominant Leukodystrophy. R. Raininko reports no disclosures. A. Lehman has received governmental research support from the Canadian Institutes for Health Research; has received academic research support from the Department of Medical Genetics at the University of British Columbia; and has received foundation/ society research support from theRareDisease Foundation and the British Columbia Clinical Genomics Network. M. Spiel-mann reports no disclosures. M.K. Koenig has served on the scientific advisory board of Novartis Pharmaceuticals; has received travel or speaker funding from Novartis Pharmaceuticals and Lundbeck; serves on the editorial board of the Journal of Child Neurology; holds a pending patent for a topical product for treatment of facial angiofibromas in Tuberous Sclerosis Complex; has served on speakers’ bureaus of Novartis Pharmaceuticals and Lundbeck; has received commercial research support from Novartis Pharmaceuticals, Reata Pharmaceuticals, EryDel S.p.A., Vtesse, Inc, Pfizer, Retrophin, Stealth, and Ultragenyx Pharmaceutical; has received governmental research support from the NIH and the Department of Defense; has received foundation/society research support from People Against Leigh’s Syndrome; and has received license fee payments from LAM Therapeutics. R. Adejumo has received commercial research support from Ultragenyx Pharmaceutical, Inc., EryDel S.p.A., Stealth BioTherapeutics, Inc, BioElectron Technology Corporation, and Retrophin, Inc; has received academic research support from the University of Texas Mitochondrial Center of Excellence; and has received foundation/society research support from People Against Leigh’s Syndrome. M. Knight reports no disclosures. R. Gavrilova has served on the scientific advisory board of the Mitochondrial Medicine Society Board. Murad Alturkustani reports no disclosures. M. Sharma serves on the editorial board of the Canadian Journal of Neurological Sciences. Robert Hammond reports no disclosures. W.A. Gahl has received travel funding from the Cystinosis Research Network; serves on the editorial board of Molecular Genetics and Metabolism; receives ManNAc licensing royalties; and has received governmental research funding from the NIH. C. Toro is an employee of the NIH. A. Brusco has served on the editorial boards of Frontiers in Aging Neuroscience and Frontiers in Neurology; holds patents for a new method for SCA1-3,6,7 genetic diagnosis and for allele-specific antisense therapy for ADLD; has received academic research support from the University of Torino; and has received foundation/society
Publisher Copyright:
© American Academy of Neurology.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - ObjectiveClinical, radiologic, and molecular analysis of patients with genomic deletions upstream of the LMNB1 gene.MethodsDetailed neurologic, MRI examinations, custom array comparative genomic hybridization (aCGH) analysis, and expression analysis were performed in patients at different clinical centers. All procedures were approved by institutional review boards of the respective institutions.ResultsFive patients from 3 independent families presented at ages ranging from 32 to 52 years with neurologic symptoms that included progressive hypophonia, upper and lower limb weakness and spasticity, and cerebellar dysfunction and MRIs characterized by widespread white matter alterations. Patients had unique nonrecurrent deletions upstream of the LMNB1, varying in size from 250 kb to 670 kb. Deletion junctions were embedded in repetitive elements. Expression analysis revealed increased LMNB1 expression in patient cells.ConclusionsOur findings confirmed the association between LMNB1 upstream deletions and leukodystrophy previously reported in a single family, expanding the phenotypic and molecular description of this condition. Although clinical and radiologic features overlapped with those of autosomal dominant leukodystrophy because of LMNB1 duplications, patients with deletions upstream of LMNB1 had an earlier age at symptom onset, lacked early dysautonomia, and appeared to have lesser involvement of the cerebellum and sparing of the spinal cord diameter on MRI. aCGH analysis defined a smaller minimal critical region required for disease causation and revealed that deletions occur at repetitive DNA genomic elements. Search for LMNB1 structural variants (duplications and upstream deletions) should be an integral part of the investigation of patients with autosomal dominant adult-onset leukodystrophy.
AB - ObjectiveClinical, radiologic, and molecular analysis of patients with genomic deletions upstream of the LMNB1 gene.MethodsDetailed neurologic, MRI examinations, custom array comparative genomic hybridization (aCGH) analysis, and expression analysis were performed in patients at different clinical centers. All procedures were approved by institutional review boards of the respective institutions.ResultsFive patients from 3 independent families presented at ages ranging from 32 to 52 years with neurologic symptoms that included progressive hypophonia, upper and lower limb weakness and spasticity, and cerebellar dysfunction and MRIs characterized by widespread white matter alterations. Patients had unique nonrecurrent deletions upstream of the LMNB1, varying in size from 250 kb to 670 kb. Deletion junctions were embedded in repetitive elements. Expression analysis revealed increased LMNB1 expression in patient cells.ConclusionsOur findings confirmed the association between LMNB1 upstream deletions and leukodystrophy previously reported in a single family, expanding the phenotypic and molecular description of this condition. Although clinical and radiologic features overlapped with those of autosomal dominant leukodystrophy because of LMNB1 duplications, patients with deletions upstream of LMNB1 had an earlier age at symptom onset, lacked early dysautonomia, and appeared to have lesser involvement of the cerebellum and sparing of the spinal cord diameter on MRI. aCGH analysis defined a smaller minimal critical region required for disease causation and revealed that deletions occur at repetitive DNA genomic elements. Search for LMNB1 structural variants (duplications and upstream deletions) should be an integral part of the investigation of patients with autosomal dominant adult-onset leukodystrophy.
UR - http://www.scopus.com/inward/record.url?scp=85065017596&partnerID=8YFLogxK
U2 - 10.1212/NXG.0000000000000305
DO - 10.1212/NXG.0000000000000305
M3 - Journal articles
AN - SCOPUS:85065017596
SN - 2376-7839
VL - 5
JO - Neurology: Genetics
JF - Neurology: Genetics
IS - 1
M1 - e305
ER -